Item request has been placed!
×
Item request cannot be made.
×
Processing Request
In-Depth Comparison of Adeno-Associated Virus Containing Fractions after CsCl Ultracentrifugation Gradient Separation.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
- Publication Information:
Original Publication: Basel, Switzerland : MDPI
- Subject Terms:
- Abstract:
Recombinant adeno-associated viruses (rAAVs) play a pivotal role in the treatment of genetic diseases. However, current production and purification processes yield AAV-based preparations that often contain unwanted empty, partially filled or damaged viral particles and impurities, including residual host cell DNA and proteins, plasmid DNA, and viral aggregates. To precisely understand the composition of AAV preparations, we systematically compared four different single-stranded AAV (ssAAV) and self-complementary (scAAV) fractions extracted from the CsCl ultracentrifugation gradient using established methods (transduction efficiency, analytical ultracentrifugation (AUC), quantitative and digital droplet PCR (qPCR and ddPCR), transmission electron microscopy (TEM) and enzyme-linked immunosorbent assay (ELISA)) alongside newer techniques (multiplex ddPCR, multi-angle light-scattering coupled to size-exclusion chromatography (SEC-MALS), multi-angle dynamic light scattering (MADLS), and high-throughput sequencing (HTS)). Suboptimal particle separation within the fractions resulted in unexpectedly similar infectivity levels. No single technique could simultaneously provide comprehensive insights in the presence of both bioactive particles and contaminants. Notably, multiplex ddPCR revealed distinct vector genome fragmentation patterns, differing between ssAAV and scAAV. This highlights the urgent need for innovative analytical and production approaches to optimize AAV vector production and enhance therapeutic outcomes.
- References:
Methods Mol Biol. 2019;1950:85-106. (PMID: 30783969)
Int J Mol Sci. 2022 Oct 22;23(21):. (PMID: 36361506)
Eur J Pharm Biopharm. 2023 Aug;189:68-83. (PMID: 37196871)
Gene Ther. 2024 May;31(5-6):285-294. (PMID: 38374348)
Front Physiol. 2019 Mar 05;10:168. (PMID: 30890951)
NAR Genom Bioinform. 2020 Sep 28;2(4):lqaa074. (PMID: 33575623)
Anal Bioanal Chem. 2022 Jan;414(2):747-758. (PMID: 34595561)
Mol Ther Methods Clin Dev. 2023 Jun 12;30:103-121. (PMID: 37746246)
Nat Biotechnol. 2015 Jul;33(7):750-4. (PMID: 26098449)
Hum Gene Ther Methods. 2018 Jun;29(3):146-155. (PMID: 29706115)
Hum Gene Ther Methods. 2019 Aug;30(4):127-136. (PMID: 31140327)
Anal Biochem. 2023 Nov 1;680:115311. (PMID: 37666384)
Biotechnol J. 2021 Jan;16(1):e2000025. (PMID: 32975881)
Mol Ther Methods Clin Dev. 2021 Feb 17;20:740-754. (PMID: 33738328)
Gene Ther. 2023 Aug;30(7-8):641-648. (PMID: 36977769)
Hum Gene Ther Methods. 2019 Aug;30(4):144-152. (PMID: 31368356)
BMC Biotechnol. 2018 Nov 1;18(1):70. (PMID: 30384832)
Mol Ther. 2016 Feb;24(2):287-297. (PMID: 26437810)
Biophys J. 2000 Mar;78(3):1606-19. (PMID: 10692345)
Hum Gene Ther. 2021 Aug;32(15-16):850-861. (PMID: 33397196)
PLoS One. 2015 Mar 04;10(3):e0118270. (PMID: 25739099)
Mol Ther Methods Clin Dev. 2018 Nov 01;11:180-190. (PMID: 30533449)
Gene Ther. 2010 Apr;17(4):503-10. (PMID: 19956269)
Mol Ther Methods Clin Dev. 2021 Aug 26;23:87-97. (PMID: 34631929)
Hum Gene Ther Methods. 2012 Feb;23(1):1-7. (PMID: 22428975)
Front Med (Lausanne). 2022 Feb 09;8:809118. (PMID: 35223884)
Mol Ther Methods Clin Dev. 2018 Nov 22;13:14-26. (PMID: 30591923)
Sci Rep. 2021 Feb 4;11(1):3012. (PMID: 33542328)
Hum Gene Ther Methods. 2015 Aug;26(4):147-57. (PMID: 26222983)
Gene Ther. 2019 Jun;26(6):240-249. (PMID: 30962536)
Mol Ther. 2006 Jul;14(1):45-53. (PMID: 16713360)
Mol Ther Methods Clin Dev. 2023 Jul 19;30:288-302. (PMID: 37583716)
Mol Ther Methods Clin Dev. 2020 Oct 01;19:341-346. (PMID: 33145370)
Mol Ther. 2005 Jul;12(1):171-8. (PMID: 15963933)
Pharmaceutics. 2021 Apr 20;13(4):. (PMID: 33923984)
Hum Gene Ther. 2022 Apr;33(7-8):371-388. (PMID: 35293222)
Electrophoresis. 2022 May;43(9-10):1107-1117. (PMID: 34821392)
PLoS One. 2022 Jun 3;17(6):e0269139. (PMID: 35657790)
Mol Ther Methods Clin Dev. 2021 Sep 01;23:254-262. (PMID: 34703846)
J Pharm Sci. 2021 Oct;110(10):3375-3384. (PMID: 34186069)
Mol Ther. 2003 Jan;7(1):122-8. (PMID: 12573625)
Mol Ther. 2004 Nov;10(5):844-54. (PMID: 15509502)
Front Microbiol. 2019 Jul 17;10:1570. (PMID: 31379763)
Biotechnol J. 2021 Jan;16(1):e2000016. (PMID: 33064875)
J Virol. 2001 Dec;75(24):12279-87. (PMID: 11711618)
Mol Ther Methods Clin Dev. 2018 Feb 13;9:130-141. (PMID: 29766023)
Methods. 2013 May 1;60(3):248-56. (PMID: 23639868)
Mol Ther Methods Clin Dev. 2014 Aug 13;1:14034. (PMID: 26015974)
Mol Ther Methods Clin Dev. 2018 Jul 27;10:223-236. (PMID: 30112419)
- Grant Information:
P4-0407; L4-3180; 1000-20-0105; 1000-21-0105; S-ZDR/22-27/0105 Slovenian Research Agency
- Contributed Indexing:
Keywords: CsCl ultracentrifugation gradient; Illumina sequencing; analytical methods; analytical ultracentrifugation (AUC); digital droplet PCR (ddPCR); recombinant adeno-associated viruses (rAAVs); size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS); transmission electron microscopy (TEM)
- Accession Number:
1KSV9V4Y4I (Cesium)
GNR9HML8BA (cesium chloride)
0 (Chlorides)
- Publication Date:
Date Created: 20240829 Date Completed: 20240829 Latest Revision: 20240903
- Publication Date:
20240903
- Accession Number:
PMC11360810
- Accession Number:
10.3390/v16081235
- Accession Number:
39205208
No Comments.